TSXV:ADK

Stock Analysis Report

Executive Summary

DIAGNOS Inc. provides software-based interpretation services in Canada, the United States, Kenya, the United Arab Emirates, Saudi Arabia, Mexico, and internationally.

Snowflake

Fundamentals

Weak fundamentals or lack of information.

Risks

  • DIAGNOS has significant price volatility in the past 3 months.
  • DIAGNOS is not covered by any analysts.

Share Price & News

How has DIAGNOS's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

2.1%

TSXV:ADK

1.3%

CA Healthcare Services

-0.9%

CA Market


1 Year Return

-62.3%

TSXV:ADK

-53.0%

CA Healthcare Services

-6.1%

CA Market

ADK underperformed the Healthcare Services industry which returned -53% over the past year.

ADK underperformed the Market in Canada which returned -6.1% over the past year.


Share holder returns

ADKIndustryMarket
7 Day2.1%1.3%-0.9%
30 Day-14.0%7.9%-3.4%
90 Day-14.0%-6.9%-3.1%
1 Year-62.3%-62.3%-53.0%-53.0%-2.8%-6.1%
3 Year-30.0%-30.0%29.6%29.6%13.2%3.1%
5 Year-71.2%-71.2%49.9%49.0%10.8%-4.7%

Price Volatility Vs. Market

How volatile is DIAGNOS's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is DIAGNOS undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether DIAGNOS is trading at an attractive price based on the cash flow it is expected to produce in the future. But as DIAGNOS has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of ADK’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through DIAGNOS regulatory filings.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is DIAGNOS expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

26.1%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as DIAGNOS has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has DIAGNOS performed over the past 5 years?

-11.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

DIAGNOS does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare DIAGNOS's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare DIAGNOS's 1-year growth to the North America Healthcare Services industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if DIAGNOS has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.


Return on Assets

It is difficult to establish if DIAGNOS has efficiently used its assets last year compared to the North America Healthcare Services industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if DIAGNOS improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.


Next Steps

Financial Health

How is DIAGNOS's financial position?


Financial Position Analysis

DIAGNOS's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

DIAGNOS's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

DIAGNOS has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.

Irrelevant to check if DIAGNOS's debt level has increased considering it has negative shareholder equity.


Balance Sheet

Low level of unsold assets.

DIAGNOS has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

DIAGNOS has less than a year of cash runway based on current free cash flow.

DIAGNOS has less than a year of cash runway if free cash flow continues to grow at historical rates of 2% each year.


Next Steps

Dividend

What is DIAGNOS's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate DIAGNOS's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate DIAGNOS's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as DIAGNOS has not reported any payouts.

Unable to verify if DIAGNOS's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as DIAGNOS has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of DIAGNOS's salary, the management and board of directors tenure and is there insider trading?

1.7yrs

Average board tenure


CEO

André Larente 0

15.2yrs

Tenure

CA$392,314

Compensation

Mr. Andre Larente has been the Chief Executive Officer and President of Diagnos Inc. since June 22, 2004. Mr. Larente has been an Executive Director of Diagnos Inc. since September 21, 2000 and served as i ...


CEO Compensation Analysis

André's remuneration is higher than average for companies of similar size in Canada.

André's compensation has been consistent with company performance over the past year, both up more than 20%.


Board Age and Tenure

1.7yrs

Average Tenure

61yo

Average Age

The average tenure for the DIAGNOS board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyCA$17,50025 Dec 18
Maurice Pinsonnault Management Inc.
EntityCompany
Shares50,000
Max PriceCA$0.35
BuyCA$35,00021 Dec 18
Maurice Pinsonnault Management Inc.
EntityCompany
Shares100,000
Max PriceCA$0.35
BuyCA$750,00914 Nov 18
Maurice Pinsonnault Management Inc.
EntityCompany
Shares1,500,000
Max PriceCA$0.50
BuyCA$50,00004 Nov 18
Georges Hébert
EntityIndividual
Role
Chairman of the Board
Chairman
Shares100,000
Max PriceCA$0.50

Ownership Breakdown


Management Team

  • André Larente

    CEO, President & Executive Director

    • Tenure: 15.2yrs
    • Compensation: CA$392.31k
  • Marc-André Massue

    VP of Finance

    • Tenure: 11.3yrs
    • Compensation: CA$211.42k
  • Guillermo Robles

    Vice President of Sales

    • Tenure: 0.0yrs
    • Compensation: CA$159.75k
  • Hadi Chakor Djelthia

    Chief Medical Officer

    • Tenure: 0.0yrs

Board Members

  • François Côté (61yo)

    Director

    • Tenure: 0.2yrs
  • Georges Hébert (71yo)

    Chairman

    • Tenure: 2.1yrs
    • Compensation: CA$31.95k
  • André Larente

    CEO, President & Executive Director

    • Tenure: 15.2yrs
    • Compensation: CA$392.31k
  • David Wong

    Member of the Scientific Advisory Board

    • Tenure: 10.0yrs
  • David LeBrun

    Member of the Scientific Advisory Board

    • Tenure: 9.9yrs
  • Reid Maclellan (35yo)

    Director

    • Tenure: 1.3yrs
  • Jean-Francois Yale

    Director

    • Tenure: 0.6yrs
  • Francois Cote

    Director

    • Tenure: 0.2yrs

Company Information

DIAGNOS Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: DIAGNOS Inc.
  • Ticker: ADK
  • Exchange: TSXV
  • Founded: 1998
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: CA$9.786m
  • Shares outstanding: 39.94m
  • Website: https://www.diagnos.ca

Location

  • DIAGNOS Inc.
  • 7005 Taschereau Boulevard
  • Suite 340
  • Brossard
  • Quebec
  • J4Z 1A7
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ADKTSXV (TSX Venture Exchange)YesCommon SharesCACADNov 2000
4D4ADB (Deutsche Boerse AG)YesCommon SharesDEEURNov 2000
DGNO.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDNov 2000

Biography

DIAGNOS Inc. provides software-based interpretation services in Canada, the United States, Kenya, the United Arab Emirates, Saudi Arabia, Mexico, and internationally. It offers image analysis services thro ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/24 23:35
End of Day Share Price2019/08/23 00:00
Earnings2019/03/31
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.